Granules India’s Unit V facility in Visakhapatnam completes USFDA inspection with zero 483 observations

This facility manufactures APIs & formulations of oncology and non-oncology products.

Granules India posts Q3 FY24 consolidated PAT at Rs. 125.65 Cr

Granules India has reported total income of Rs. 1156.23 crores during the period ended December 31, 2023

Granules India received ANDA approval for Pantoprazole Sodium Delayed-Release Tablets

Pantoprazole Sodium Delayed-Release Tablets are indicated for short-term treatment of Erosive Esophagitis associated with GERD

Granules India received ANDA approval for Sildenafil for oral suspension

The current annual U.S. market for Sildenafil for Oral Suspension is approximately $43 million

Granules India Q2 FY24 PAT drops 30% at Rs. 102 Cr

Sales in the US region grew well, partially offset by the decline in the LATAM and European regions

Granules India receives ANDA approval for Esomeprazole Magnesium Delayed-Release Capsules

Short-term treatment of heartburn and other symptoms associated with gastroesophageal reflux disease (GERD)

Briefs: Granules India

Granules India received approval from Brazilian Health Regulatory Agency ANVISA

Granules India posts Q1 FY24 revenue from operations at Rs. 985.5 Cr

API, PFI, and Finished dosages contribute 30%, 15%, and 55% of revenue from operations respectively for Q1FY24

Granules India received USFDA approval for the ANDA filed for metoprolol succinate ER tablets

Granules India announces approval for Acetaminophen and Ibuprofen Tablets

This product will be launched through Granules Consumer Health (GCH) division